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In eligible patients, high-dose melphalan with autologous hematopoietic cell transplantation (auto-HCT) can provide deep hematological responses and reversal of amyloid-related organ dysfunction. [2] [3] [4] Use of G-CSF has become the standard method for hematopoietic progenitor cell (HPC) mobilization in AL amyloidosis as chemotherapy-based mobilization in this setting has largely been abandoned owing to the high risk of cardiac events, infections, bleeding complications and mortality. [5] [6] [7] However, significant morbidity, including death has also been reported during or immediately after G-CSF-based mobilization in AL amyloidosis patients. 8, 9 In addition, significant weight gain and mobilization failure are other important complications with this approach. 10, 11 Plerixafor, a selective and reversible antagonist of CXCR-4 (C-X-C a chemokine receptor type 4) has proven efficacy in combination with G-CSF for HPC mobilization, primarily in the context of myeloma and non-Hodgkin lymphoma. 12 We recently reported superior efficacy, significantly less weight gain and no mobilization failures with an upfront plerixafor plus abbreviatedcourse G-CSF (G+P) mobilization approach in AL amyloidosis, compared with a historical control of G-CSF-only group. 13 Whether routine addition of plerixafor for HPC mobilization in AL amyloidosis leads to higher mobilization costs is not known and warrants investigation in this era of escalating healthcare costs. Herein, we report a cost analysis of HPC mobilization with G+P in AL compared with G-alone approach.
AL amyloidosis patients undergoing HPC mobilization at our center from 2004 to 2013 constitute the study population. Between 2004 and 2008 HPC mobilization was done with G-CSF alone administered daily at 10 μg/kg s.c. with apheresis starting on day 5. Apheresis and daily G-CSF injections were continued for up to four consecutive collections or until a target yield of ⩾ 5 × 10 6 CD34+ cells/kg patient body weight, whichever occurred first. Beginning in 10/2009 as a quality-improvement initiative to reduce G-CSF exposure and associated complications during HPC collection in AL amyloidosis, mobilization was modified by adding plerixafor at 0.24 mg/kg (s.c.) on the evening of day 3 of G-CSF (10 μg/kg) administration,~11 h before the initiation of apheresis. All collections were performed in the outpatient setting using the Cobe Spectra Apheresis System (Terumo BCT, Lakewood, CO, USA) by processing three to four blood volumes. It is the institutional policy at our transplant center to collect a minimum of ⩾ 2 × 10 Data on costs of HPC mobilization, apheresis and cryopreservation were assessed as described previously by Shaughnessy et al.
14
Costs were calculated per patient in both the groups (including all reimbursable procedures, hospitalizations and costs of all medications and supportive care measures during mobilization). A subset analysis was performed to evaluate the cost of mobilization for patients undergoing apheresis for a total of 1, 2 and 3 sessions. The costs related to mobilization and apheresis are shown in Table 1 and are adjusted to reflect 2014 US $. Cost of hospitalization during mobilization was estimated from the reimbursement rates of the Centers for Medicare and Medicaid Services (CMS) inpatient Prospective Payment System and Diagnosis-Related Groups. Median national CMS reimbursement rates were used to determine the mobilization, apheresis and cryopreservation costs. Medication prices were based on the average sale price for each product. The average sale price was estimated from the average wholesale price by using methods described by Shaughnessy et al.
The baseline characteristics and mobilization efficacy results of 49 consecutive patients included in this analysis were previously published 13 and are summarized in Supplementary Tables S1  and S2 , respectively, of the Supplementary Appendix. Baseline characteristics were well balanced between the G-CSF alone (n = 25) and G+P group (n = 24), except higher pretransplant bortezomib exposure in the G+P group (P o 0.001). The efficacy characteristics are shown in Supplementary Table S2 . G+P strategy provided a higher total CD34+ cells/kg yield (12.8 × 10 6 vs 6.3 × 10 6 ; P o 0.001). More G+P patients collected ⩾ 5 ×10 6 CD34+HPCs/kg (22 vs 16, P = 0.02) and ⩾ 10 × 10 6 CD34+ HPCs/kg (13 vs 5, P = 0.01). Four patients (16%) had mobilization failure with G-CSF alone and none with G+P. Peri-mobilization weight gain was lower with G+P strategy (median weight gain 1 vs 7 lbs, P = 0.009). Hematopoietic Cell Transplantation-Comorbidity Index was 1 (0-3) in G+P vs 3 (0-8) in the G group and the median time from diagnosis to transplant was 10 months (2-120) in G+P vs 5 months (1-121). No major cardiac events were noted between the two groups.
Mobilization costs are summarized in Table 2 . There was no significant difference in the average apheresis-related costs between the G-CSF alone and G+P groups ($8103.9 vs $6940.8, respectively; P = 0.29). The administration of plerixafor was associated with significantly lower G-CSF costs (P o 0.0001). However, despite lower G-CSF cost in the G+P group, owing to the substantial cost of plerixafor, the average total mobilization costs in the G+P group ($24 358.6; range $23 711.5-$37 819) were significantly higher compared with the G-CSF-only group ($16 158.3; range; $9310.8-24 966.8; P = 0.001). Even among patients requiring only a single day of apheresis, a significantly higher cost was seen with the G+P cohort compared with the G-CSF-only group ($18 023 vs $10 872.3; P o 0.001) as shown in Table 2 . Similarly, the average total cost of mobilization in the G+P group was significantly greater for patients requiring a total of 2, or 3 apheresis days when compared with patients requiring similar a number of apheresis sessions in the G-CSF-only cohort. No difference in the cost of blood product transfusion between the two groups was seen (P = 0.14). Similarly no difference in the cost of hospitalization between the two groups was seen (P = 0.46).
The higher average mobilization cost of the G+P group is largely because of the cost of plerixafor, an effective but expensive drug. It is possible that the reduction in the cost of plerixafor could make this strategy more cost neutral. In multiple myeloma, when compared with chemomobilization, plerixafor use appeared to be cost neutral for patients finishing mobilization on day 1 with this benefit disappearing in patients needing two or more sessions. 14, 15 In contrast, our study did not show such an effect, with higher costs in the plerixafor group, regardless of the number of total apheresis sessions. This is likely due to the fact that our study compared cost of G+P approach, with a cytokine-only method, unlike prior studies in myeloma and lymphoma where the comparator group was chemotherapy-based mobilization. Unlike the G+P HPC mobilization in myeloma or lymphoma, where plerixafor is generally given on the evening of day 4 of G-CSF administration, in our study we administered plerixafor on the evening of day 3 to reduce systemic exposure to G-CSF in order to potentially reduced cytokine-induced weight gain and complications. Although it is theoretically possible that starting plerixafor on the evening of day 4 in AL amyloidosis patient might lead to even higher CD34+ cell yields, it is unlikely to make this approach more cost effective, since the average number of apheresis sessions and incidence of hospitalization for the apheresis-related complications were similar between the two groups. Despite the higher average mobilization costs in the G+P group, our abbreviated G-CSF plus plerixafor strategy has some advantages. Four patients in the G-CSF-only group experienced mobilization failure, whereas no collection failures were observed after the addition of plerixafor to our mobilization algorithm. Patients in the G+P group had significantly less weight gain compared with the G-CSF-only group. Limited exposure to GSCF might be a contributing factor in minimizing weight gain in this group. Significant weight gain during HPC collection has previously been shown to be an independent predictor of mortality post auto-HCT in AL patients. 10 It is important to highlight that our cost analysis does not necessarily reflect the actual reimbursement and institutional overhead associated with mobilization and its complications. Hospital charges and reimbursements vary depending on transplant center's billing practices and the patient's insurance provider (Medicaid vs Medicare vs private insurance). For our cost analysis, we adopted the previously published methodologies 14, 15 to make our analysis applicable to a broader range of transplant programs.
In conclusion, our study demonstrates that plerixafor combined with an abbreviated-course of G-CSF despite providing a higher CD34+ cell collection yield and reducing peri-mobilization weight gain is associated with significantly higher mobilization costs. Whether a 'just-in-time' approach of plerixafor, as being utilized in HPC mobilization in myeloma and lymphoma patients, would be more cost neutral in AL amyloidosis warrants investigation.
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